Developer docs
API playgroundTry for free, no card

Search company profiles

Coloplast

Full company profile

uuid0000slw

Namestring
Coloplast
Legal namestring
Coloplast A/S
Websiteurl
coloplast.com
Company typeenum
Public
Founded yearint
1957
Descriptiontext

Coloplast A/S is a Denmark-headquartered (Humlebaek) publicly listed medical device company founded in 1957, organized into six core business areas: Ostomy Care (SenSura Mio platform), Continence Care (SpeediCath and Luja intermittent catheters), Interventional Urology (Titan Prime penile prosthesis, Altis sling, Durasphere EXP bulking agent), Bowel Care (Peristeen transanal irrigation), Wound and Tissue Repair (Biatain dressings plus Kerecis fish-skin biologics acquired in 2023), and Voice and Respiratory Care (voice prostheses, HMEs, tubes). The company serves more than two million patients annually across 100+ countries, anchored by chronic-condition patient cohorts and institutional healthcare buyers.

The company makes money primarily through hardware sales of medical devices and consumables, distributed via direct enterprise sales subsidiaries targeting hospitals and clinics, Group Purchasing Organization contracts with Vizient, Premier, and Novation for institutional channel access, and consumer channels (pharmacies and medical supply retailers) for direct-to-patient chronic care products. Patient support is delivered through Coloplast Care and clinician-facing services through Coloplast Professional. Manufacturing is geographically diversified across Denmark, Hungary, China (Zhuhai), Portugal (Felgueiras, with a €110M expansion announced in 2025), Costa Rica, and the United States.

Coloplast's recent strategic posture reflects a shift toward higher-growth biologics and interventional urology adjacencies, executed through Kerecis (USD 1.3 billion, 2023) and Uromedica (announced 2026), alongside new product launches such as Titan Prime, Biatain Silicone Fit, Peristeen Light, and Luja for women. The company reported 7% organic revenue growth and a 28% EBIT margin in FY2024/25 and announced a new Impact4 five-year strategy in September 2025 under new CEO Gavin Wood (effective May 1, 2026), a former Johnson & Johnson executive. Operational signals include Medicare reimbursement pressure on Kerecis, ongoing FX headwinds on DKK-reported revenue, and an active capital markets posture demonstrated by a DKK 9.2 billion directed equity issue in August 2023.

Short descriptiontext

Coloplast A/S is a Denmark-based, publicly listed medical device company manufacturing ostomy, continence, wound, interventional urology, bowel, and voice and respiratory care products for chronic-condition patients and healthcare institutions in 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersHumlebæk, Denmark
HQ citystring
Humlebæk
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ostomy care products, continence care devices, wound care dressings, medical device manufacturing, interventional urology
Industry3 codes
PRIMARYHLAHALAG
Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services
SECONDARYCRADALAK
Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Paper Goods & Disposables (Tissue, Diapers, Feminine Care)
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Biological Product (except Diagnostic) Manufacturing325414
  • Offices of Physicians62111
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Ostomy, Continence & Wound Care Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - B2B
TypeHardware Sales
Description

Direct sales of medical devices and supplies to healthcare institutions, hospitals, clinics, and healthcare providers through subsidiaries and GPO contracts

2Medical Device Sales - B2C
TypeHardware Sales
Description

Sales of consumer healthcare products directly to patients with chronic conditions through pharmacies and direct distribution

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Institutional pricing through GPO contracts
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing through Group Purchasing Organization contracts with major healthcare GPOs

GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Coloplast Care
Description

Patient support program providing practical and emotional support for people living with intimate healthcare needs

coloplast.com
+8 more records
Core offering1 text field

Coloplast manufactures and sells medical devices for intimate healthcare across six core business areas: Ostomy Care (ostomy bags including the SenSura Mio platform), Continence Care (intermittent catheters such as SpeediCath and Luja), Interventional Urology (implants, slings, and the Titan Prime penile prosthesis), Bowel Care (Peristeen transanal irrigation systems), Wound & Tissue Repair (Biatain dressings and Kerecis fish-skin biologics), and Voice and Respiratory Care (voice prostheses, HMEs, tubes and adhesives). Products are sold through both institutional healthcare channels (hospitals, clinics, GPO contracts) and direct-to-consumer channels (pharmacies, the Coloplast Care support program).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Medical Design Excellence Award winner for Conveen Optima (2007)
Product overview1 text field

Coloplast is a medical device company offering a portfolio of intimate healthcare solutions organized into six core business areas: Ostomy Care (ostomy bags including SenSura Mio), Continence Care (intermittent catheters including SpeediCath and Luja), Interventional Urology (implants, slings, Titan Prime penile prosthesis), Bowel Care (Peristeen transanal irrigation systems), Wound & Tissue Repair (Biatain dressings and Kerecis fish-skin biologics), and Voice & Respiratory Care. The company also provides support services through Coloplast Care (patient support) and Coloplast Professional (healthcare professional resources). Products range from disposable consumer devices to implantable prosthetics, with recent expansion through the 2023 acquisition of Kerecis biologics.

Product and service6 records
1Ostomy Care
CategoryOstomy Care
Description

Ostomy bags and supporting products for people living with stomas, built on the SenSura Mio platform with double-layer adhesive technology. Sold to patients through pharmacies, medical supply retailers, and the Coloplast Care support program, and to healthcare institutions for post-surgical patient care.

2Continence Care
CategoryContinence Care
Description

Intermittent catheters (SpeediCath, Luja) and collecting devices for bladder management, designed to reduce urinary tract infection risk. Used by patients with neurogenic bladder and by healthcare institutions for catheterization.

3Interventional Urology
CategoryInterventional Urology
Description

Implants, slings, and surgery tools for urological conditions, including Titan Prime inflatable penile prosthesis, Virtue incontinence sling, Altis Single Incision Sling System, and Durasphere EXP bulking agent. Targeted at urologists and surgical specialists treating erectile dysfunction, stress urinary incontinence, and pelvic floor disorders.

4Bowel Care
CategoryBowel Care
Description

Transanal irrigation systems including Peristeen and Peristeen Light for management of neurogenic bowel dysfunction and chronic constipation. Used by patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurogenic bowel conditions.

5Wound & Tissue Repair
CategoryWound & Tissue Repair
Description

Wound dressings including the Biatain family (Biatain Soft-Hold, Biatain Ibu with ibuprofen, Biatain Silicone Fit) and Kerecis fish-skin biologics for chronic wound healing, including pressure ulcers and diabetic foot ulcers. Used by wound care clinicians, hospitals, and long-term care facilities.

6Voice and Respiratory Care
CategoryVoice and Respiratory Care
Description

Voice prostheses, Heat and Moisture Exchangers (HMEs), tubes, and adhesives for laryngectomy and respiratory care patients. Used by patients who have undergone laryngectomy and by clinicians in head and neck surgical and pulmonary care.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Group Purchasing Organization contract for institutional sales to Vizient member healthcare organizations

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Group Purchasing Organization contract for institutional sales to Premier member healthcare organizations

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Group Purchasing Organization contract for institutional sales through Novation's healthcare member network

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Acquisition expanding wound care portfolio with fish skin-based regenerative tissue products

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Acquisition expanding continence care product portfolio

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct peer: a UK-listed medical device company focused on ostomy care, continence care, advanced wound care, and infusion sets. Competes head-to-head with Coloplast across SenSura Mio, SpeediCath, and Biatain equivalents.

TypeDirect peer
Description

Privately held US medical device company with a strong ostomy and continence care franchise, directly competing with Coloplast in ostomy bags and intermittent catheters.

TypeBroad incumbent
Description

German medical device and pharma company with a sizable urology, continence, and wound care portfolio (e.g., Actreen catheters, Prontosan wound solutions). Overlaps with Coloplast in catheters and wound care but operates a much broader medtech portfolio.

TypeDirect peer
Description

Global medical device player with an Advanced Wound Management franchise that directly competes with Biatain and Kerecis. Comparable in advanced wound dressings, biologics-adjacent products, and global hospital sales channels.

TypeDirect peer
Description

Swedish wound care and surgical solutions specialist (Mepilex, Mepitel). Overlaps with Coloplast in wound dressings and prevention, especially in the same European hospital channel.

TypeBroad incumbent
Description

Large-cap medtech with a urology and pelvic health franchise (slings, implants, stone management) that competes with Coloplast's Interventional Urology line, including Altis and the new Titan Prime penile prosthesis.

TypeBroad incumbent
Description

Diversified medtech with infusion systems and urology/home-care exposure. Comparable in institutional sales motion and adjacent to Coloplast's continence and home-delivered chronic-care channels.

TypeEmerging player
Description

US-listed wound care biologics company (Apligraf, Dermagraft) competing in the same advanced wound biologics segment where Kerecis operates, useful as a biologics comp for the Kerecis business.

TypeBroad incumbent
Description

Global medtech incumbent with surgical, orthopedic, and wound care adjacencies. Less direct overlap but competes for hospital capital budgets and urology/OR procedure share.

TypeEmerging player
Description

US medtech with urology and continence catheters and surgical products that overlap with Coloplast's intermittent catheter and interventional urology portfolios.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coloplast

Ostomy, Continence & Wound Care Medical Devicescoloplast.com

Coloplast A/S is a Denmark-based, publicly listed medical device company manufacturing ostomy, continence, wound, interventional urology, bowel, and voice and respiratory care products for chronic-condition patients and healthcare institutions in 100+ countries.

What Coloplast does

Coloplast A/S is a Denmark-headquartered (Humlebaek) publicly listed medical device company founded in 1957, organized into six core business areas: Ostomy Care (SenSura Mio platform), Continence Care (SpeediCath and Luja intermittent catheters), Interventional Urology (Titan Prime penile prosthesis, Altis sling, Durasphere EXP bulking agent), Bowel Care (Peristeen transanal irrigation), Wound and Tissue Repair (Biatain dressings plus Kerecis fish-skin biologics acquired in 2023), and Voice and Respiratory Care (voice prostheses, HMEs, tubes). The company serves more than two million patients annually across 100+ countries, anchored by chronic-condition patient cohorts and institutional healthcare buyers.

The company makes money primarily through hardware sales of medical devices and consumables, distributed via direct enterprise sales subsidiaries targeting hospitals and clinics, Group Purchasing Organization contracts with Vizient, Premier, and Novation for institutional channel access, and consumer channels (pharmacies and medical supply retailers) for direct-to-patient chronic care products. Patient support is delivered through Coloplast Care and clinician-facing services through Coloplast Professional. Manufacturing is geographically diversified across Denmark, Hungary, China (Zhuhai), Portugal (Felgueiras, with a €110M expansion announced in 2025), Costa Rica, and the United States.

Coloplast's recent strategic posture reflects a shift toward higher-growth biologics and interventional urology adjacencies, executed through Kerecis (USD 1.3 billion, 2023) and Uromedica (announced 2026), alongside new product launches such as Titan Prime, Biatain Silicone Fit, Peristeen Light, and Luja for women. The company reported 7% organic revenue growth and a 28% EBIT margin in FY2024/25 and announced a new Impact4 five-year strategy in September 2025 under new CEO Gavin Wood (effective May 1, 2026), a former Johnson & Johnson executive. Operational signals include Medicare reimbursement pressure on Kerecis, ongoing FX headwinds on DKK-reported revenue, and an active capital markets posture demonstrated by a DKK 9.2 billion directed equity issue in August 2023.

Coloplast firmographics

Firmographics
Name
Coloplast
Legal name
Coloplast A/S
Website
https://coloplast.com
Company type
Public
Founded year
1957
Operating status
Operating
Headcount range
10,001+ employees
Short description
Coloplast A/S is a Denmark-based, publicly listed medical device company manufacturing ostomy, continence, wound, interventional urology, bowel, and voice and respiratory care products for chronic-condition patients and healthcare institutions in 100+ countries.
Ownership category
akta.pro rank

Coloplast industry classification

Industry
Product category
Ostomy, Continence & Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Offices of Physicians (62111)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHALAG
Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services
SECONDARYCRADALAK
Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Paper Goods & Disposables (Tissue, Diapers, Feminine Care)

Keywords

  • Ostomy care products
  • Continence care devices
  • Wound care dressings
  • Medical device manufacturing
  • Interventional urology

Where Coloplast is headquartered

Location

Headquarters

HQ city
Humlebæk
HQ country
Denmark
HQ region
Europe

Offices6 records

Markets served

Coloplast business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Device Sales - B2B: Direct sales of medical devices and supplies to healthcare institutions, hospitals, clinics, and healthcare providers through subsidiaries and GPO contracts
  2. Medical Device Sales - B2C: Sales of consumer healthcare products directly to patients with chronic conditions through pharmacies and direct distribution

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInstitutional pricing through GPO contracts

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Coloplast product offering

Product offering

Core offering

Coloplast manufactures and sells medical devices for intimate healthcare across six core business areas: Ostomy Care (ostomy bags including the SenSura Mio platform), Continence Care (intermittent catheters such as SpeediCath and Luja), Interventional Urology (implants, slings, and the Titan Prime penile prosthesis), Bowel Care (Peristeen transanal irrigation systems), Wound & Tissue Repair (Biatain dressings and Kerecis fish-skin biologics), and Voice and Respiratory Care (voice prostheses, HMEs, tubes and adhesives). Products are sold through both institutional healthcare channels (hospitals, clinics, GPO contracts) and direct-to-consumer channels (pharmacies, the Coloplast Care support program).

Product overview

Coloplast is a medical device company offering a portfolio of intimate healthcare solutions organized into six core business areas: Ostomy Care (ostomy bags including SenSura Mio), Continence Care (intermittent catheters including SpeediCath and Luja), Interventional Urology (implants, slings, Titan Prime penile prosthesis), Bowel Care (Peristeen transanal irrigation systems), Wound & Tissue Repair (Biatain dressings and Kerecis fish-skin biologics), and Voice & Respiratory Care. The company also provides support services through Coloplast Care (patient support) and Coloplast Professional (healthcare professional resources). Products range from disposable consumer devices to implantable prosthetics, with recent expansion through the 2023 acquisition of Kerecis biologics.

Differentiator

Problem solved

Functional benefit

Brands

  • Coloplast Care: Patient support program providing practical and emotional support for people living with intimate healthcare needs
  • Coloplast Professional
  • SenSura Mio
  • SpeediCath
  • Biatain
  • Peristeen
  • Conveen
  • Titan Prime
  • Kerecis

Products and services

  • Ostomy Care Ostomy bags and supporting products for people living with stomas, built on the SenSura Mio platform with double-layer adhesive technology. Sold to patients through pharmacies, medical supply retailers, and the Coloplast Care support program, and to healthcare institutions for post-surgical patient care.
  • Continence Care Intermittent catheters (SpeediCath, Luja) and collecting devices for bladder management, designed to reduce urinary tract infection risk. Used by patients with neurogenic bladder and by healthcare institutions for catheterization.
  • Interventional Urology Implants, slings, and surgery tools for urological conditions, including Titan Prime inflatable penile prosthesis, Virtue incontinence sling, Altis Single Incision Sling System, and Durasphere EXP bulking agent. Targeted at urologists and surgical specialists treating erectile dysfunction, stress urinary incontinence, and pelvic floor disorders.
  • Bowel Care Transanal irrigation systems including Peristeen and Peristeen Light for management of neurogenic bowel dysfunction and chronic constipation. Used by patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurogenic bowel conditions.
  • Wound & Tissue Repair Wound dressings including the Biatain family (Biatain Soft-Hold, Biatain Ibu with ibuprofen, Biatain Silicone Fit) and Kerecis fish-skin biologics for chronic wound healing, including pressure ulcers and diabetic foot ulcers. Used by wound care clinicians, hospitals, and long-term care facilities.
  • Voice and Respiratory Care Voice prostheses, Heat and Moisture Exchangers (HMEs), tubes, and adhesives for laryngectomy and respiratory care patients. Used by patients who have undergone laryngectomy and by clinicians in head and neck surgical and pulmonary care.

Quantifiable outcome

  • Medical Design Excellence Award winner for Conveen Optima (2007)

Companies that use Coloplast

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Coloplast technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Coloplast partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • VizientcoreChannel Partner/ Reseller/ DistributorGroup Purchasing Organization contract for institutional sales to Vizient member healthcare organizations
  • PremiercoreChannel Partner/ Reseller/ DistributorGroup Purchasing Organization contract for institutional sales to Premier member healthcare organizations
  • NovationcoreChannel Partner/ Reseller/ DistributorGroup Purchasing Organization contract for institutional sales through Novation's healthcare member network
  • KerecismajorStrategic or Co-development PartnerAcquisition expanding wound care portfolio with fish skin-based regenerative tissue products
  • UromedicamajorStrategic or Co-development PartnerAcquisition expanding continence care product portfolio

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Coloplast competitors and assessment

Company assessment

Direct peers

  • ConvaTec Group: Closest direct peer: a UK-listed medical device company focused on ostomy care, continence care, advanced wound care, and infusion sets. Competes head-to-head with Coloplast across SenSura Mio, SpeediCath, and Biatain equivalents.
  • Hollister Incorporated: Privately held US medical device company with a strong ostomy and continence care franchise, directly competing with Coloplast in ostomy bags and intermittent catheters.
  • Smith & Nephew: Global medical device player with an Advanced Wound Management franchise that directly competes with Biatain and Kerecis. Comparable in advanced wound dressings, biologics-adjacent products, and global hospital sales channels.
  • Mölnlycke Health Care: Swedish wound care and surgical solutions specialist (Mepilex, Mepitel). Overlaps with Coloplast in wound dressings and prevention, especially in the same European hospital channel.

Broad incumbents

  • B. Braun: German medical device and pharma company with a sizable urology, continence, and wound care portfolio (e.g., Actreen catheters, Prontosan wound solutions). Overlaps with Coloplast in catheters and wound care but operates a much broader medtech portfolio.
  • Boston Scientific: Large-cap medtech with a urology and pelvic health franchise (slings, implants, stone management) that competes with Coloplast's Interventional Urology line, including Altis and the new Titan Prime penile prosthesis.
  • Baxter International: Diversified medtech with infusion systems and urology/home-care exposure. Comparable in institutional sales motion and adjacent to Coloplast's continence and home-delivered chronic-care channels.
  • Stryker: Global medtech incumbent with surgical, orthopedic, and wound care adjacencies. Less direct overlap but competes for hospital capital budgets and urology/OR procedure share.

Emerging players

  • Organogenesis Holdings: US-listed wound care biologics company (Apligraf, Dermagraft) competing in the same advanced wound biologics segment where Kerecis operates, useful as a biologics comp for the Kerecis business.
  • Teleflex: US medtech with urology and continence catheters and surgical products that overlap with Coloplast's intermittent catheter and interventional urology portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Coloplast social profiles

Digital presence

Coloplast financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coloplast leadership team

Management profile

Number of profiles

Profiles4 records

Coloplast subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Coloplast funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coloplast M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coloplast

What does Coloplast do?

Coloplast manufactures and sells medical devices for intimate healthcare across six core business areas: Ostomy Care (ostomy bags including the SenSura Mio platform), Continence Care (intermittent catheters such as SpeediCath and Luja), Interventional Urology (implants, slings, and the Titan Prime penile prosthesis), Bowel Care (Peristeen transanal irrigation systems), Wound & Tissue Repair (Biatain dressings and Kerecis fish-skin biologics), and Voice and Respiratory Care (voice prostheses, HMEs, tubes and adhesives). Products are sold through both institutional healthcare channels (hospitals, clinics, GPO contracts) and direct-to-consumer channels (pharmacies, the Coloplast Care support program).

Is Coloplast a public or private company?

Coloplast is a public company. It is classified as public and is currently operating.

When was Coloplast founded?

Coloplast was founded in 1957. It employs 10,001+ people.

Where is Coloplast based?

Coloplast is headquartered in Humlebæk, Denmark, in the Europe region.

How does Coloplast make money?

Two revenue lines are on record. Medical Device Sales - B2B is the primary driver. The others are medical Device Sales - B2C.

Who are Coloplast's main competitors?

Direct peers on record are ConvaTec Group, Hollister Incorporated, Smith & Nephew and Mölnlycke Health Care. Broad incumbents are B. Braun, Boston Scientific, Baxter International and Stryker. Emerging players are Organogenesis Holdings and Teleflex.

Does Coloplast have an API?

No public API is recorded for Coloplast.

What industry is Coloplast in?

Coloplast's product category is Ostomy, Continence & Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAG, Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection), with a secondary code of HSABAKAH, Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaColoplast: Turnaround Is Underway, But Upside Is Limited (OTCMKTS:CLPBF)Coloplast A/S revised its mid-term guidance to 5–7% organic growth and mid-20% EBIT margins, citing a DKK 3.0B impairment that impacted full-year results. Adjusted EPS grew 39.1% and free cash flow rose 16.4% year-over-year, though China, European reimbursement, and U.S. bidding remain key risks.Business & FinancialNotice Of Annual General Meeting 2026Coloplast A/S will hold its Annual General Meeting on Tuesday, 1 December 2026 at 3:30 pm CET at its premises in Humlebæk, Denmark. The meeting notice is enclosed, and the company's mission and values are also stated.The future of tradingColoplast Announces Annual General MeetingColoplast will hold its annual general meeting on December 1, 2026, at the Aage Louis-Hansen Auditorium in Humlebæk, Denmark. The meeting is scheduled for that date, with no further details provided.TradingViewNotice of Annual General Meeting 2026Coloplast A/S will hold its Annual General Meeting on Tuesday, 1 December 2026 at 3:30 pm CET at its premises in Humlebæk, Denmark. The notice includes contact details for investors, analysts, and media, with the English version prevailing in case of discrepancies.The future of tradingNotice of Annual General Meeting 2026Coloplast A/S will hold its Annual General Meeting on Tuesday, 1 December 2026 at 3:30 pm CET at its premises in Humlebæk, Denmark. The notice is enclosed, and contact details for investors and media are provided.InvestegateNotice of Annual General Meeting 2026Coloplast A/S will hold its Annual General Meeting on Tuesday, 1 December 2026 at 3:30 pm CET at its premises in Humlebæk, Denmark. The notice includes contact details for investors, analysts, and media, with the English version prevailing in case of discrepancies.The future of tradingColoplast Presents Revised 2030 Ambition for 5-7% Annual Organic GrowthColoplast revised its 2030 ambition to 5-7% annual organic growth and a mid-20% EBIT margin in constant currencies. FY2026/27 guidance calls for 5-7% organic growth and an EBIT margin around 25% in constant currencies. FY2025/26 revenue rose 4% to DKK 28.94 billion, with organic growth of 6%.Nate콜로플라스트, 중국 사업 축소…현지 영업인력 80명 감원 : 네이트 뉴스Coloplast is cutting about 80 jobs in its China sales organization, citing delayed market recovery. The company expects China's business to stabilize by 2027-2028, as China accounts for about 4% of its revenue. It plans to continue operations with a more efficient structure.Seeking AlphaColoplast A/S (CLPBY) Q4 2026 Earnings Call TranscriptColoplast's Q4 2026 earnings call revealed a revised 2030 financial ambition, targeting 5-7% annual organic growth and mid-20s EBIT margin. The company also aims for a 20% return on invested capital by 2029-30, citing a more challenging external environment and increased long-term investments.BorsenColoplast-topchef skruer ned: Analyti­kere ser nødvendig nulstil­lingColoplast CEO Gavin Wood has cut the company's long-term growth ambitions, citing new subsidy rules and inflation pressure. Analysts have long questioned the targets and called for a reset, which Wood has now implemented. The move follows six months in the role.